|  |   | 
		| (4 intermediate revisions not shown.) | 
| Line 1: | Line 1: | 
|  | + |  | 
|  | ==Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor== |  | ==Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor== | 
| - | <StructureSection load='3g42' size='340' side='right' caption='[[3g42]], [[Resolution|resolution]] 2.10Å' scene=''> | + | <StructureSection load='3g42' size='340' side='right'caption='[[3g42]], [[Resolution|resolution]] 2.10Å' scene=''> | 
|  | == Structural highlights == |  | == Structural highlights == | 
| - | <table><tr><td colspan='2'>[[3g42]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3G42 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3G42 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[3g42]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3G42 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3G42 FirstGlance]. <br> | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=792:N-{[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}-5-METHYL-D-TRYPTOPHAN'>792</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> | 
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2a8h|2a8h]], [[1bkc|1bkc]], [[2i47|2i47]], [[1zxc|1zxc]]</td></tr>
 | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=792:N-{[4-(BUT-2-YN-1-YLOXY)PHENYL]SULFONYL}-5-METHYL-D-TRYPTOPHAN'>792</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | 
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ADAM17, CSVP, TACE ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3g42 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3g42 OCA], [https://pdbe.org/3g42 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3g42 RCSB], [https://www.ebi.ac.uk/pdbsum/3g42 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3g42 ProSAT]</span></td></tr> | 
| - | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/ADAM_17_endopeptidase ADAM 17 endopeptidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.86 3.4.24.86] </span></td></tr>
 | + |  | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3g42 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3g42 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3g42 RCSB], [http://www.ebi.ac.uk/pdbsum/3g42 PDBsum]</span></td></tr> | + |  | 
|  | </table> |  | </table> | 
|  | == Disease == |  | == Disease == | 
| - | [[http://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN]] Defects in ADAM17 are a cause of neonatal inflammatory skin and bowel disease (NISBD) [MIM:[http://omim.org/entry/614328 614328]]. NISBD is a disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized.<ref>PMID:22010916</ref>  | + | [https://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN] Defects in ADAM17 are a cause of neonatal inflammatory skin and bowel disease (NISBD) [MIM:[https://omim.org/entry/614328 614328]. NISBD is a disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized.<ref>PMID:22010916</ref>  | 
|  | == Function == |  | == Function == | 
| - | [[http://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN]] Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Also involved in the activation of Notch pathway (By similarity).<ref>PMID:12441351</ref> <ref>PMID:20592283</ref>  | + | [https://www.uniprot.org/uniprot/ADA17_HUMAN ADA17_HUMAN] Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Also involved in the activation of Notch pathway (By similarity).<ref>PMID:12441351</ref> <ref>PMID:20592283</ref>  | 
|  | == Evolutionary Conservation == |  | == Evolutionary Conservation == | 
|  | [[Image:Consurf_key_small.gif|200px|right]] |  | [[Image:Consurf_key_small.gif|200px|right]] | 
|  | Check<jmol> |  | Check<jmol> | 
|  |   <jmolCheckbox> |  |   <jmolCheckbox> | 
| - |     <scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/g4/3g42_consurf.spt"</scriptWhenChecked> | + |     <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/g4/3g42_consurf.spt"</scriptWhenChecked> | 
| - |     <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | + |     <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked> | 
|  |     <text>to colour the structure by Evolutionary Conservation</text> |  |     <text>to colour the structure by Evolutionary Conservation</text> | 
|  |   </jmolCheckbox> |  |   </jmolCheckbox> | 
| - | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf]. | + | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3g42 ConSurf]. | 
|  | <div style="clear:both"></div> |  | <div style="clear:both"></div> | 
|  | <div style="background-color:#fffaf0;"> |  | <div style="background-color:#fffaf0;"> | 
| Line 31: | Line 30: | 
|  | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |  | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | 
|  | </div> |  | </div> | 
|  | + | <div class="pdbe-citations 3g42" style="background-color:#fffaf0;"></div> | 
|  |  |  |  | 
|  | ==See Also== |  | ==See Also== | 
| - | *[[A Disintegrin And Metalloproteinase|A Disintegrin And Metalloproteinase]] | + | *[[A Disintegrin And Metalloproteinase 3D structures|A Disintegrin And Metalloproteinase 3D structures]] | 
|  | == References == |  | == References == | 
|  | <references/> |  | <references/> | 
|  | __TOC__ |  | __TOC__ | 
|  | </StructureSection> |  | </StructureSection> | 
| - | [[Category: ADAM 17 endopeptidase]] |  | 
|  | [[Category: Homo sapiens]] |  | [[Category: Homo sapiens]] | 
| - | [[Category: Aplasca, A]] | + | [[Category: Large Structures]] | 
| - | [[Category: Gopalsamy, A]] | + | [[Category: Aplasca A]] | 
| - | [[Category: K., Park]] | + | [[Category: Gopalsamy A]] | 
| - | [[Category: Levin, J I]] | + | [[Category: Levin JI]] | 
| - | [[Category: Xu, W]] | + | [[Category: Park K]] | 
| - | [[Category: Zhang, Y H]] | + | [[Category: Xu W]] | 
| - | [[Category: Cleavage on pair of basic residue]] | + | [[Category: Zhang YH]] | 
| - | [[Category: Glycoprotein]]
 | + |  | 
| - | [[Category: Hydrolase]]
 | + |  | 
| - | [[Category: Membrane]]
 | + |  | 
| - | [[Category: Metal-binding]]
 | + |  | 
| - | [[Category: Metalloprotease]]
 | + |  | 
| - | [[Category: Notch signaling pathway]]
 | + |  | 
| - | [[Category: Phosphoprotein]]
 | + |  | 
| - | [[Category: Protease]]
 | + |  | 
| - | [[Category: Sh3-binding]]
 | + |  | 
| - | [[Category: Tace-inhibitor complex]]
 | + |  | 
| - | [[Category: Tace/adam-17]]
 | + |  | 
| - | [[Category: Transmembrane]]
 | + |  | 
| - | [[Category: Zn-endopeptidase]]
 | + |  | 
| - | [[Category: Zymogen]]
 | + |  | 
|  |   Structural highlights   Disease ADA17_HUMAN Defects in ADAM17 are a cause of neonatal inflammatory skin and bowel disease (NISBD) [MIM:614328. NISBD is a disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized.[1] 
   Function ADA17_HUMAN Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Also involved in the activation of Notch pathway (By similarity).[2] [3] 
   Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
 
  Publication Abstract from PubMed A novel series of non-hydroxamate tryptophan sulfonamide derivatives containing a butynyloxy P1' moiety was identified as inhibitors of TNF-alpha converting enzyme (TACE). The structure-activity relationship of the series was examined via substitution on the tryptophan indole ring. Of the compounds investigated, 2-(4-(but-2-ynyloxy)phenylsulfonamido)-3-(1-(4-methoxybenzyl)-1H-indol-3-y l)propanoic acid (12p) has the best in vitro potency against isolated TACE enzyme with an IC(50) of 80 nM. Compound 12p also shows good selectivity over MMP-1, -13, -14.
 Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.,Park K, Gopalsamy A, Aplasca A, Ellingboe JW, Xu W, Zhang Y, Levin JI Bioorg Med Chem. 2009 Jun 1;17(11):3857-65. Epub 2009 Apr 22. PMID:19410464[4]
 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
  See Also  References ↑ Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, O'Toole EA, Martin JE, Lindley K, Vulliamy T, Abrams DJ, MacDonald TT, Harper JI, Kelsell DP. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011 Oct 20;365(16):1502-8. doi: 10.1056/NEJMoa1100721. PMID:22010916 doi:10.1056/NEJMoa1100721↑ Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem. 2003 Jan 31;278(5):3386-94. Epub 2002 Nov 18. PMID:12441351 doi:10.1074/jbc.M208326200↑ Rabquer BJ, Amin MA, Teegala N, Shaheen MK, Tsou PS, Ruth JH, Lesch CA, Imhof BA, Koch AE. Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J Immunol. 2010 Aug 1;185(3):1777-85. doi: 10.4049/jimmunol.1000556. Epub 2010, Jun 30. PMID:20592283 doi:10.4049/jimmunol.1000556↑ Park K, Gopalsamy A, Aplasca A, Ellingboe JW, Xu W, Zhang Y, Levin JI. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors. Bioorg Med Chem. 2009 Jun 1;17(11):3857-65. Epub 2009 Apr 22. PMID:19410464 doi:10.1016/j.bmc.2009.04.033
 
 |